ARJO Aktie

 

Arjo will issue its interim report for Q2 on Friday July 11 at 07:00 CEST, followed by a conference call at 08:00 CEST, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO. Fund managers, analysts and media are invited to participate in a conference call and presentation of the report via the following link (https://arjo.events.inderes.com/q2-report-2025) and a recorded version of the conference is accessible for three years here (https://arjo.events.inderes.com/q2-report-2025). Those who wish to ask questions verbally in the teleconference will...

Arjo has completed the first issue of SEK 1 billion under the recently established MTN program. The issue received considerable interest from the market and the transaction was quickly oversubscribed. The bond was issued with floating rate and a maturity of 5 years, and are to be traded at Nasdaq Stockholm. Arjo established the MTN program on May 14 2025 in order to further broaden its sources of funding. The MTN program is arranged by Danske Bank with SEB acting as joint bookrunner. For more information, please contact: Nils-Johan Granberg, VP Group Treasury +46 706 081 062...

Arjo AB has established a medium-term note programme with a framework amount of SEK 5 billion. Arjo's debt financing currently consists mainly of bank loans and corporate certificates. Through the new program, Arjo aims to further broaden its sources of financing. The programme has today been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). The base prospectus will be made available on Arjo's website. Danske Bank has been appointed as arranger of the MTN program and will also act as dealer together with SEB. Mannheimer Swartling acted as...

Arjo AB (publ) held the Annual General Meeting on Tuesday 29 April 2025 in Malmö. At the Annual General Meeting the following was resolved: Adoption of the Income Statement and the Balance Sheet The Annual General Meeting adopted the Income Statement and the Balance Sheet as well as the Consolidated Income Statement and the Consolidated Balance Sheet for the financial year 2024. Dividend In accordance with the proposal of the Board of Directors and the CEO, the Annual General Meeting resolved to declare a dividend of SEK 0.95 per share. 2 May 2025 was determined as record date...

”We are starting the year with growth in line with our target, a strengthened order book and an improved gross margin. Profitability was held back by the stronger SEK, but adjusted for currency, adjusted operating profit increased during the quarter. We remain focused on driving the business and strengthening our long-term competitiveness with new launches in our two largest product categories,” says Niclas Sjöswärd, Interim President & CEO of Arjo.   January-March 2025 in brief · Net sales increased to SEK 2,863 M (2,759). Net sales grew organically by 3.4%. · The gross...

Das Instrument A39 SE0010468116 ARJO AB B EQUITY wird cum Dividende/Zinsen gehandelt am 29.04.2025 und ex Dividende/Zinsen am 30.04.2025 The instrument A39 SE0010468116 ARJO AB B EQUITY has its pre-dividend/interest day on 29.04.2025 and its ex-dividend/interest day on 30.04.2025...

Arjo, a global leader in medical device technology, today announces the launch of Maxi Move 5[®], the latest generation of one of the company's best-selling products. The new top-of-the-line mobile patient floor lift features several innovative technical solutions designed to help reduce caregiver injuries and optimize efficiencies in care situations. For five decades Arjo has been driving innovation within mobile patient floor lifts and remains in a leading position in the patient handling segment, and once again breaks new ground with Maxi Move 5. Patient handling remains one of Arjo's...

Arjo will issue its interim report for Q1 on Tuesday April 29 at 14:00 CEST, followed by a conference call at 15:00 CEST, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO. Fund managers, analysts and media are invited to participate in a conference call and presentation of the report via the following link (https://arjo.events.inderes.com/q1-report-2025) and a recorded version of the conference is accessible for three years here (https://arjo.events.inderes.com/q1-report-2025). Those who wish to ask questions verbally in the teleconference...

Arjo's Annual and Sustainability Report for 2024 is now available on the Group's website. The Annual and Sustainability Report is published in Swedish and English and a printed version of the report can be ordered from the Group's website (https://www.arjo.com/int/about-us/investors/). For more information, please contact: Maria Nilsson, EVP Communication & Public Relations Tel: +46 734 244 515 Email: maria.nilsson@arjo.com Erik Roslund, Investor Relations & Corporate Communications Tel: +46 768 996 303 Email: erik.roslund@arjo.com   This information is information...

Arjo has appointed Eva Brike as new EVP Human Resources & Sustainability starting June 1, 2025. Eva succeeds Marion Gullstrand, who after a long operational career has chosen to pursue new opportunities. Eva Brike most recently held the position of Vice President People & Culture at Atos Medical, part of Coloplast. She has a solid background that also includes positions at Rosti Group and Resurs Bank. “We are very pleased to welcome Eva Brike to Arjo. Her experience and expertise will be an asset in the continued work to strengthen both the organization and our leadership and culture –...

The shareholders of Arjo AB (publ), Corporate ID No. 559092-8064, are hereby invited to attend the Annual General Meeting (the “AGM”) on Tuesday, 29 April 2025 at 5.00 p.m. CEST, at Glasklart, Dockplatsen 1, Malmö, Sweden. The Arjo Board of Directors has decided to make it possible for shareholders who do not wish to attend the AGM physically to exercise their right to vote by postal voting before the AGM in accordance with the regulations in Arjo's Articles of Association. In the case of postal voting, any questions must be submitted in advance. RIGHT TO ATTEND AND NOTICE OF...

Dawes-Redman CTG Analysis™, used for fetal diagnostics, has received 510(k) approval from the U.S. Food and Drug Administration (FDA). Arjo's diagnostics division, Huntleigh Healthcare, has been the exclusive global distributor of the solution for many years, and the approval means it can now be offered to customers also in the US market. The analysis evaluates factors such as basal heart rate, sinusoidal rhythms, and the short-term variation of the fetal heart rate, a factor that is impossible to calculate manually. “Being able to offer the Dawes Redman analysis to customers in the...

”We close the year with a solid fourth quarter with growth and increased profitability. We have a strong foundation to stand on and enter 2025 with positive momentum in key markets such as the US and UK. In parallel, we remain committed to our efforts for continued profitability improvements moving forward,” says Niclas Sjöswärd, Interim President & CEO of Arjo.   October-December 2024 in brief · Net sales increased to SEK 2,989 M (2,879). Net sales grew organically by 3.1%. · The gross margin was 44.7% (45.3). · Adjusted EBITDA increased 6.5% to SEK 653 M (614). ·...

Arjo will issue its year-end report for 2024 on Thursday January 30 at 07:00 CET, followed by a conference call at 08:00 CET, hosted by Niclas Sjöswärd, interim President and CEO, and Christofer Carlsson, interim CFO. Fund managers, analysts and media are invited to participate in a conference call and presentation of the report via the following link (https://arjo.events.inderes.com/q4-report-2024). Please note that the telephone conference will replace the report presentation originally scheduled to be held in conjunction with the now postponed Capital Markets Update. Those who...

Arjo, a global leader in medical device technology, is today presenting Symbliss[®], an innovative assisted bathing system setting a new standard in the healthcare industry. Symbliss supports workflows that reduce caregiver injuries, optimize efficiencies in care settings and enables person-centered wellness experiences. Arjo has a longstanding tradition of developing hygiene solutions, with the systematic approach to both bathing and transfer equipment going back more than 50 years.  “Symbliss is the latest example of how we innovate premium products and solutions for real-life care...

Due to Niclas Sjöswärd taking on the role of acting CEO for Arjo following Joacim Lindoff's departure from the company, Christofer Carlsson has been appointed interim CFO, effective today. Christofer currently holds the position of Vice President Corporate Control at Arjo, encompassing functions such as Group Accounting, Tax, and Business and Sustainability Controlling. Christofer has been with Arjo since 2017 and has previous experience from finance positions at Gambro and BE Group among others.   ”Christofer knows our financial operations very well. I have great confidence in him...

In light of this morning's communication that Joacim Lindoff is leaving his position as CEO of Arjo and to avoid speculation, Arjo is releasing a summary of the year-end report for 2024 before the publication of the complete year-end report on January 30. Summary of Q4 2024: · Arjo's net sales increased to 2 989 MSEK (2 879), corresponding to an organic net sales growth of 3.1 percent. · Adjusted EBITDA amounted to 653 MSEK (614). · Adjusted EBIT grew 9.7 percent to 375 MSEK (342).   "We are delivering a strong fourth quarter with continued organic growth and...

The Board of Directors of Arjo and Joacim Lindoff have come to an agreement which implicates Joacim leaving his position as President & CEO of Arjo, a role he has held since 2017. Niclas Sjöswärd, currently CFO of Arjo, has been appointed interim President & CEO. The process of recruiting a new CEO will be initiated immediately. The Board of Directors would like to thank Joacim for the period of close to eight years that we have had the opportunity to work together. Arjo has since its spinoff developed into a company with a solid foundation under Joacim's leadership. However, work...

Arjo invites analysts, institutional investors and media to a Capital Markets Update at GT30, Grev Turegatan 30, in Stockholm on January 30th, in conjunction with the release of the company's year-end report 2024. Possibility to join digitally will be offered as well, with the option of asking questions online. The day will begin at 09:00 CET with a review of the year-end report. This will be followed by presentations from President and CEO Joacim Lindoff, CFO Niclas Sjöswärd and Jonas Cederhage, EVP Supply Chain and R&D. The program is expected to finish no later than 12:00 CET....

In line with previous communication, Arjo has during the fourth quarter terminated the distribution agreement with Bruin Biometrics and has now accordingly divested related assets. Consequently, exceptional items will be charged with 55 million SEK in the fourth quarter related to this. The amount consists of a non-cash book value of 70 million SEK related to inventory, rental assets and remaining distribution rights, as well as a positively cash flow affecting compensation of approximately 15 million SEK from the divestment of these to Bruin Biometrics. As previously communicated, the...